Drugs used to treat diabetes and obesity, or GLP-1 (Glucagon-like peptide-1), will be a significant growth driver for ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

A slowdown of the digestive tract (gastroparesis) can be a serious side effect, though. Researchers who analyzed the health records of 16 million people revealed that pancreatitis and bowel ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

From cost-effectiveness of procedures to disc replacement outcomes, researchers published multiple findings about spine surgery in 2024.

Discover the advantages and disadvantages of incorporating weight loss drugs and injectables into your self-care routine ...

Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...

The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular ...

The drug Ozempic has surged in popularity in recent years, due to its proven ability to tackle obesity and diabetes safely.